Skip to main content
TipRanks
Go Ultimate75% OFF

First Tracks Biotherapeutics Inc (TRAX) Stock Price & Analysis

57 Followers

TRAX Stock Chart & Stats

$44.46-$0.04(-0.09%)
At close: 4:00 PM EST
$30$40$50Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$43.80 - $46.27
52-Week Range
$14.72 - $54.78
Previous Close
$44.50
Volume
N/A
Average Volume (3M)
962.59K
Market Cap
$1.87B
Enterprise Value
$1.12B
Total Cash (Recent Filing)
$155.63M
Total Debt (Recent Filing)
$3.77M
Price to Earnings (P/E)
―
Beta
0.48
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Validation

Positive Phase 1b efficacy and tolerability data provide clinical validation for ANB033 and support progression toward later-stage development. If confirmed in subsequent studies, this evidence could strengthen the company’s product prospects and improve its ability to address an unmet need in celiac disease.

Low Financial Leverage

Very low debt relative to equity limits interest and repayment burdens compared with a highly leveraged biotech structure. This gives the company greater financial flexibility to direct available resources toward research and development, although it does not eliminate the need for future funding.

Pipeline Expansion

Plans to test ANB033 across celiac disease, vitiligo, and another indication broaden the potential application of the lead program. Multiple development paths can diversify clinical opportunity and create more avenues for future value if efficacy is demonstrated across diseases.

Bears Say

No Commercial Revenue

The absence of revenue means the company currently lacks a commercial funding engine and remains dependent on capital markets or other financing sources. Negative gross profit and ongoing development spending also indicate that commercial self-sufficiency is not yet established.

Worsening Losses

Large and worsening net losses show that operating costs are rising faster than any offsetting income, leaving profitability structurally distant. Continued losses can reduce the capital available for development and increase the financial resources required before programs can generate returns.

Heavy Cash Burn And Funding Risk

Accelerating operating cash outflows demonstrate that reported losses are translating into substantial real cash consumption. Persistently negative free cash flow implies ongoing funding needs, while reliance on additional financing can constrain strategic flexibility and create dilution pressure.

First Tracks Biotherapeutics Inc News

TRAX FAQ

What was First Tracks Biotherapeutics Inc’s price range in the past 12 months?
First Tracks Biotherapeutics Inc lowest stock price was $14.72 and its highest was $54.78 in the past 12 months.
What is First Tracks Biotherapeutics Inc’s market cap?
First Tracks Biotherapeutics Inc’s market cap is $1.87B.
When is First Tracks Biotherapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were First Tracks Biotherapeutics Inc’s earnings last quarter?
First Tracks Biotherapeutics Inc released its earnings results on Nov 03, 2026. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.903 by $0.023.
Is First Tracks Biotherapeutics Inc overvalued?
According to Wall Street analysts First Tracks Biotherapeutics Inc’s price is currently Undervalued.
Does First Tracks Biotherapeutics Inc pay dividends?
First Tracks Biotherapeutics Inc does not currently pay dividends.
What is First Tracks Biotherapeutics Inc’s EPS estimate?
First Tracks Biotherapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does First Tracks Biotherapeutics Inc have?
First Tracks Biotherapeutics Inc has 42,017,902 shares outstanding.
What happened to First Tracks Biotherapeutics Inc’s price movement after its last earnings report?
First Tracks Biotherapeutics Inc reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.903. Following the earnings report the stock price went up 5.826%.
Which hedge fund is a major shareholder of First Tracks Biotherapeutics Inc?
Hedge funds hold First Tracks Biotherapeutics Inc shares: the largest hedge-fund position in First Tracks Biotherapeutics Inc is 72,325,162 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology